- Real-world study shows the effectiveness and safety of 2L Gilotrif following 1L IO plus CT in the treatment of squamous cell carcinoma of the lung
- Results: Median overall TOT for patients who received 2L afatinib & CT (7.3mos. & 4.2mos.); the incidence of irAEs occurred in 6 patients while no reported irAES in the chemotherapy cohort.
- Separate data presented indicate Gilotrif activity in TKI-naïve patients with G719X/L861Q/S768I non-resistant EGFR mutation-positive NSCLC. Gilotrif is indicated for metastatic NSCLC whose tumors have non-resistant EGFR mutations and for advanced squamous cell carcinoma of the lung, progressed after treatment with platinum-based CT
Click here to read the full press release/ article | Ref: PRNewswire | Image: GMP News